New York, March 27, 2014 -- Moody's Investors Service changed Baxter International Inc's rating outlook to negative from stable following the company's announcement that it plans to pursue a separation of its bioscience business into an independent public company. At the same time, Moody's affirmed Baxter's A3 and Prime-2 ratings.
Vollständigen Artikel bei Moodys lesen